Literature DB >> 35498362

A child with bronchiectasis, chronic mucocutaneous candidiasis, and hypothyroidism secondary to STAT1 gain-of-function mutation: A case report and review of the literature.

Dhuha Alidrisi1, Lama Maksood2, Wed Alqahtani2, Faisal Minshawi3, Abdullah Aburziza4, Waleed F Janem1, Mohammed A Almatrafi4.   

Abstract

STAT 1 GOF mutations are a rare cause of childhood primary immunodeficiency. Recurrent mucocutaneous candidiasis, chest infections, and autoimmune disease are all classic phenotype presentations. Rapid identification and diagnosis of this debilitating disease using whole exon sequencing may improve outcomes and minimize long-term sequelae.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  STAT 1; immunodeficiency; mucocutaneous candidiasis

Year:  2022        PMID: 35498362      PMCID: PMC9040560          DOI: 10.1002/ccr3.5791

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


BACKGROUND

Signal transducer and activator of transcription 1 (STAT1) are critical STAT family members, which play an essential role in cell differentiation, metabolism, and apoptosis via the Janus family tyrosine kinase–signal transducer and activator of transcription (JAK‐STAT) pathway. Moreover, STAT1 is required for signaling type 1 interferon (α, β) and type 2 interferon (γ). Germline heterozygous mutation of the STAT1 leads to primary immunodeficiency, classified as defects in the immune response to pathogens. Mutations to STAT1 impair the host immune system and increase susceptibility to different pathogens, including mycobacteria, fungi, and viruses. Mutations to STAT1 could be either loss‐of‐function (LOF) or gain‐of‐function (GOF) mutations, and they exhibit distinct clinical phenotypes. LOF mutations cause the failure of interferon‐g‐ and interferon α/β‐mediated immunity leading to susceptibility to mycobacteria and viruses. , On the contrary, STAT1 GOF defects are caused by mutations in the coiled‐coil domain, which impair the nuclear dephosphorylation of activated STAT1. , STAT1 hyperphosphorylation has been linked to chronic mucocutaneous candidiasis (CMC) due to impaired IL‐17 immunity. Patients with IL‐17 deficiency are at risk of developing recurrent candida infections, viral infections, and bacterial infections, including atypical mycobacterium organisms. Herein, we present a child with a scalp abscess, mucocutaneous candidiasis, and bronchiectasis, all of which suggest an underlying immune deficiency.

CASE PRESENTATION

An 8‐year‐old female patient presents with fever, chronic cough, and scalp swelling. Her past medical history is noteworthy for recurrent tinea capitis infections that failed to respond to prolonged oral antifungal therapy with griseofulvin. Additionally, her parents reported a history of persistent oral thrush despite topical therapy with nystatin, and recurrent chest infections necessitating multiple hospitalizations since she was 2 years old. Neonatal history is remarkable for 2 weeks of neonatal intensive care unit stays for neonatal sepsis. She was immunized up to 1 year of age primarily due to her parents' lack of follow‐up. She lives with her parents and two healthy siblings. Family history is unremarkable for recurrent infections or similar conditions. At admission, she was febrile to 39.2 C, but with normal heart rate (90 beats/minute), respiratory rate (14 breaths/minutes), and blood pressure for age (95/54). Growth parameters indicated a failure to thrive (weight: 16 kg at −3.66 SD, 0.1% percentile) and severe short stature (height: 99.5 cm at −5.50 SD, 0.1% percentile). There were no signs of dysmorphic features. Pertinent physical findings include clubbing in both hands and feet, tender fluctuant scalp abscess, oral thrush, and diffuse bilateral crepitations all over her chest. Initial laboratory findings included normocytic normochromic anemia (Hb = 9.7 g/dl), an elevated erythrocyte sedimentation rate (ESR = 40 mm/Hr), and elevated c‐reactive protein levels (CRP = 7.9 mg/dl). The parameters of liver and kidney function tests were within the normal range. The scalp abscess was drained and cultured, and the patient was empirically started on clindamycin pending culture results. The patient's history of recurrent chest infections, mucocutaneous candidiasis, and failure to thrive raises concerns about an underlying immunodeficiency. Serology for the human immunodeficiency virus (HIV) was negative. Additional immunological testing was performed and interpreted in accordance with her age. Apart from an elevated IgA level, she had normal results for age for both immunoglobulin levels (IgM = 168 mg/dl, IgG = 1505 mg/dl, IgA = 862 mg/dl, IgE = 4.5 IU/ML) and lymphocytes subset panel (Lymphocytes absolute count = 1.891 10⁽³⁾/μl, T‐lymphocytes (CD3+) = 1.185 cells/ul, T‐ suppressor cells (CD3+/CD8+) = 309 cells/ul, T‐helper cells (CD3+/CD4+) = 812 cells/ul, CD4+/CD8+ ratio = 2.63), NK‐cells (CD16+/CD56+) = 122 cells/ul, B‐lymphocytes (CD19+) = 562 cells/ul. Whole exon sequencing (WES) revealed a heterozygous missense variant in the STAT1 gene (NM_007315, 4: C. 1154C>T p. Thr385Met). The GOF STAT1 immunodeficiency was confirmed based on the mutation variant in the STAT 1 gene and the patient's clinical presentation. There was no family history of recurrent infections or similar conditions, suggesting de novo mutation. Nonetheless, her parents' consanguineous marriage may justify testing them for inherited mutations. Signal transducer and activator of transcription 1 immunodeficiency is associated with CMC, bronchiectasis, recurrent respiratory infections, and endocrinopathy due to underlying autoimmune processes. Indeed, our patient was found to have bilateral diffuse bronchiectasis, bilateral reticular‐nodular densities, and multiple small hilar lymph nodes on a chest CT scan. Tuberculosis workup included QuantiFERON‐TB Gold and gastric aspirate for acid‐fast bacilli stain, and cultures were negative. She was found to have severe hypothyroidism (TSH = 100 uIU/ml normal range is 0.27–4.20, FT4 = 0.9 pmol/L normal range is 9–19), which provides a plausible explanation for her significant short stature. Anti‐Tissue Transglutaminase and thyroid antibodies were all negative. Her scalp abscess and oral thrush resolved after 2 weeks of clindamycin and fluconazole, respectively. She responded very well to levothyroxine, showing marked improvement in her growth acceleration on subsequent outpatient visits. She was referred to a tertiary hospital for multidisciplinary service management and consideration of stem cell transplantation vs. Janus kinase 1 inhibitors.

DISCUSSION

Recurrent infections with various microorganisms are a critical indicator of primary immunodeficiency. This report describes an 8‐year‐old female with multiple complaints, including failure to thrive, MRSA abscesses on the scalp, tinea capitis, recurrent chest infections complicated by bronchiectasis, and persistent oral candida infection. Due to the patient's unusual clinical presentation, we suspected a primary immunodeficiency, including humoral immunity (antibody production) and T‐cell defects. Other than elevated IgA, antibody production and lymphocyte subgroups (CD3+, CD4+, and CD8+) were normal in our patient. Yu et al. reported a similar finding of an elevated IgA level in a patient with a STAT 1 GOF mutation. WES was carried out and revealed a heterozygous missense variant in the STAT1 gene consistent with the clinical phenotype associated with STAT1 GOF mutations. Signal transducer and activator of transcription 1 GOF mutations cause CMC and autoimmunity mainly because of augmented T‐helper 1 response, deficiency in T‐helper 17 development, and antifungal response. , , CMC is the most common manifestation of STAT1 GOF mutations owing to the critical role of impaired IL‐17 immunity in CMC development. CMC presents primarily as skin, nail, and oropharynx candida species infection. , Toubiana et al. recruited 274 patients with STAT1 GOF mutations from five continents. CMC is the most common manifestation of STAT1 GOF mutations, accounting for 98% of recruited patients. Approximately 74% of patients in the study had recurrent bacterial infections. The most frequently encountered infections were lower respiratory tract infections (47%), recurrent sinusitis (44%), and skin and soft tissue infections in the form of folliculitis, cellulitis, and abscess (28%). Streptococcus pneumoniae, pseudomonas aeruginosa, and staphylococcus aureus are the most common isolated bacterial organisms in patients with STAT1 GOF mutations. Mycobacterial infections account for a small proportion of all bacterial infections among study participants (6%). In 38% of patients, viral infections were observed, with the most common causative organisms being HSV and VZV. This case was diagnosed with tinea capitis of the scalp, which has been reported in 16% of the previous studies. Trichophyton and Microsporon species were the causative organisms in 52% of these cases of dermatophyte fungal infections affecting the scalp, skin, and nails. Toubiana et al. and Van FL et al. reported that a significant proportion of patients with STAT 1 GOF mutations also have concurrent autoimmune conditions. The most frequently reported autoimmune conditions were hypothyroidism, type 1 diabetes mellitus, vasculitis, systemic lupus erythematosus disease, or skin conditions such as psoriasis or vitiligo. , Although our patient did have severe hypothyroidism, thyroid autoantibodies were not detected. The patient's hospitalization was complicated by a mild COVID‐19 infection. In literature, three patients with STAT 1 GOF mutations had mild COVID‐19 disease, , , suggesting that STAT1 GOF mutations are not associated with severe COVID‐19 infection. , , Further research may be conducted to determine the effect of STAT1 GOF on the severity of COVID‐19 infection. Antimicrobial prophylaxis on a long‐term basis is critical in patients with STAT 1 GOF mutations to prevent recurrent infections. According to Toubiana et al., approximately 74% of patients required antifungal prophylaxis, with fluconazole being the first‐line option, followed by itraconazole and posaconazole. Antibacterial prophylaxis was used in 26% of patients, with trimethoprim‐sulfamethoxazole as the primary bacterial prophylaxis to prevent recurrent staphylococcus aureus infections. In a minority of patients, antiviral therapy, immunoglobulin, biological agents, and stem cell transplantation were used. Our patient was discharged home on prophylactic fluconazole 6 mg/kg/day three times per week, and trimethoprim‐sulfamethoxazole 2.5 mg/kg/day three times per week, with a referral to a tertiary hospital for consideration of stem cell transplantation or the initiation of rituximab.

CONCLUSION

Although STAT 1 GOF mutations are extremely rare, clinicians should consider them when making a differential diagnosis of patients with chronic cutaneous candidiasis, bronchiectasis, and stunted growth. Additionally, this report emphasizes the value of WES as a rapid and effective method for diagnosing STAT 1 GOF mutations.

CONFLICTS OF INTEREST

None.

AUTHOR CONTRIBUTION

DA was involved in case diagnosis, study design, literature search, and manuscript editing. LM was involved in data gathering, literature review, and manuscript writing. WA, FM, AA, and WJ contributed to the interpretation of data and manuscript editing. MA assisted with the literature search and critical revision of the manuscript. Final manuscript approved by all authors.

ETHICAL APPROVAL

Obtained.

CONSENT

The patient's parent provided written informed consent to publish this case.
  17 in total

Review 1.  Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?

Authors:  Anne Puel; Capucine Picard; Sophie Cypowyj; Desa Lilic; Laurent Abel; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2010-07-30       Impact factor: 7.486

2.  Progressive bronchiectasis and CMC in a patient with STAT1 GOF - a rare case of primary immunodeficiency.

Authors:  Hanna Dmeńska; Małgorzata Pac; Małgorzata Skomska-Pawliszak; Barbara Pietrucha; Beata Wolska-Kuśnierz; Barbara Piątosa; Justyna Komarnicka; Edyta Heropolitańska-Pliszka
Journal:  Adv Respir Med       Date:  2020

Review 3.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

Review 4.  Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species.

Authors:  László Maródi; Sophie Cypowyj; Beáta Tóth; Liudmyla Chernyshova; Anne Puel; Jean-Laurent Casanova
Journal:  J Allergy Clin Immunol       Date:  2012-10-03       Impact factor: 10.793

5.  Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.

Authors:  Julie Toubiana; Satoshi Okada; Julia Hiller; Matias Oleastro; Macarena Lagos Gomez; Juan Carlos Aldave Becerra; Marie Ouachée-Chardin; Fanny Fouyssac; Katta Mohan Girisha; Amos Etzioni; Joris Van Montfrans; Yildiz Camcioglu; Leigh Ann Kerns; Bernd Belohradsky; Stéphane Blanche; Aziz Bousfiha; Carlos Rodriguez-Gallego; Isabelle Meyts; Kai Kisand; Janine Reichenbach; Ellen D Renner; Sergio Rosenzweig; Bodo Grimbacher; Frank L van de Veerdonk; Claudia Traidl-Hoffmann; Capucine Picard; Laszlo Marodi; Tomohiro Morio; Masao Kobayashi; Desa Lilic; Joshua D Milner; Steven Holland; Jean-Laurent Casanova; Anne Puel
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

6.  Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1.

Authors:  Safa Baris; Fayhan Alroqi; Ayca Kiykim; Elif Karakoc-Aydiner; Ismail Ogulur; Ahmet Ozen; Louis-Marie Charbonnier; Mustafa Bakır; Kaan Boztug; Talal A Chatila; Isil B Barlan
Journal:  J Clin Immunol       Date:  2016-07-05       Impact factor: 8.317

7.  Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.

Authors:  Luyan Liu; Satoshi Okada; Xiao-Fei Kong; Alexandra Y Kreins; Sophie Cypowyj; Avinash Abhyankar; Julie Toubiana; Yuval Itan; Magali Audry; Patrick Nitschke; Cécile Masson; Beata Toth; Jérome Flatot; Mélanie Migaud; Maya Chrabieh; Tatiana Kochetkov; Alexandre Bolze; Alessandro Borghesi; Antoine Toulon; Julia Hiller; Stefanie Eyerich; Kilian Eyerich; Vera Gulácsy; Ludmyla Chernyshova; Viktor Chernyshov; Anastasia Bondarenko; Rosa María Cortés Grimaldo; Lizbeth Blancas-Galicia; Ileana Maria Madrigal Beas; Joachim Roesler; Klaus Magdorf; Dan Engelhard; Caroline Thumerelle; Pierre-Régis Burgel; Miriam Hoernes; Barbara Drexel; Reinhard Seger; Theresia Kusuma; Annette F Jansson; Julie Sawalle-Belohradsky; Bernd Belohradsky; Emmanuelle Jouanguy; Jacinta Bustamante; Mélanie Bué; Nathan Karin; Gizi Wildbaum; Christine Bodemer; Olivier Lortholary; Alain Fischer; Stéphane Blanche; Saleh Al-Muhsen; Janine Reichenbach; Masao Kobayashi; Francisco Espinosa Rosales; Carlos Torres Lozano; Sara Sebnem Kilic; Matias Oleastro; Amos Etzioni; Claudia Traidl-Hoffmann; Ellen D Renner; Laurent Abel; Capucine Picard; László Maródi; Stéphanie Boisson-Dupuis; Anne Puel; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2011-07-04       Impact factor: 14.307

8.  Chronic Candida infection, bronchiectasis, immunoglobulin abnormalities, and stunting: a case report of a natural mutation of STAT1 (c.986C>G) in an adolescent male.

Authors:  Yali Yu; Fei Xu; Hui Shen; Jiang Wu
Journal:  BMC Infect Dis       Date:  2021-01-07       Impact factor: 3.090

9.  SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?

Authors:  Paloma Guisado Hernández; Pilar Blanco Lobo; Olaf Neth; Peter Olbrich; Isabel Villaoslada; Beatriz de Felipe; José M Lucena; Guillermo Martín Gutierrez; María José Castro; Alicia Gutiérrez Valencia; María Isabel Sánchez Codez; Mirella Gaboli
Journal:  J Clin Immunol       Date:  2021-06-09       Impact factor: 8.317

10.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study.

Authors:  Isabelle Meyts; Giorgia Bucciol; Isabella Quinti; Bénédicte Neven; Alain Fischer; Elena Seoane; Eduardo Lopez-Granados; Carla Gianelli; Angel Robles-Marhuenda; Pierre-Yves Jeandel; Catherine Paillard; Vijay G Sankaran; Yesim Yilmaz Demirdag; Vassilios Lougaris; Alessandro Aiuti; Alessandro Plebani; Cinzia Milito; Virgil Ash Dalm; Kissy Guevara-Hoyer; Silvia Sánchez-Ramón; Liliana Bezrodnik; Federica Barzaghi; Luis Ignacio Gonzalez-Granado; Grant R Hayman; Gulbu Uzel; Leonardo Oliveira Mendonça; Carlo Agostini; Giuseppe Spadaro; Raffaele Badolato; Annarosa Soresina; François Vermeulen; Cedric Bosteels; Bart N Lambrecht; Michael Keller; Peter J Mustillo; Roshini S Abraham; Sudhir Gupta; Ahmet Ozen; Elif Karakoc-Aydiner; Safa Baris; Alexandra F Freeman; Marco Yamazaki-Nakashimada; Selma Scheffler-Mendoza; Sara Espinosa-Padilla; Andrew R Gennery; Stephen Jolles; Yazmin Espinosa; M Cecilia Poli; Claire Fieschi; Fabian Hauck; Charlotte Cunningham-Rundles; Nizar Mahlaoui; Klaus Warnatz; Kathleen E Sullivan; Stuart G Tangye
Journal:  J Allergy Clin Immunol       Date:  2020-09-24       Impact factor: 10.793

View more
  1 in total

1.  A child with bronchiectasis, chronic mucocutaneous candidiasis, and hypothyroidism secondary to STAT1 gain-of-function mutation: A case report and review of the literature.

Authors:  Dhuha Alidrisi; Lama Maksood; Wed Alqahtani; Faisal Minshawi; Abdullah Aburziza; Waleed F Janem; Mohammed A Almatrafi
Journal:  Clin Case Rep       Date:  2022-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.